ATE261278T1 - Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen - Google Patents

Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen

Info

Publication number
ATE261278T1
ATE261278T1 AT95924078T AT95924078T ATE261278T1 AT E261278 T1 ATE261278 T1 AT E261278T1 AT 95924078 T AT95924078 T AT 95924078T AT 95924078 T AT95924078 T AT 95924078T AT E261278 T1 ATE261278 T1 AT E261278T1
Authority
AT
Austria
Prior art keywords
mum
microspheres
neuroactive
microcapsules
ingredients
Prior art date
Application number
AT95924078T
Other languages
English (en)
Inventor
Amanda Mcrae-Mcfarland
Annica B Dahlstrom
Deborah L Dillon
Thomas R Tice
David W Mason
Original Assignee
Southern Res Inst
Amanda Mcrae-Mcfarland
Annica B Dahlstrom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst, Amanda Mcrae-Mcfarland, Annica B Dahlstrom filed Critical Southern Res Inst
Application granted granted Critical
Publication of ATE261278T1 publication Critical patent/ATE261278T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
AT95924078T 1994-06-29 1995-06-28 Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen ATE261278T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/268,177 US6517859B1 (en) 1990-05-16 1994-06-29 Microcapsules for administration of neuroactive agents
PCT/US1995/008123 WO1996000537A1 (en) 1994-06-29 1995-06-28 Microcapsules for administration of neuroactive agents

Publications (1)

Publication Number Publication Date
ATE261278T1 true ATE261278T1 (de) 2004-03-15

Family

ID=23021810

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95924078T ATE261278T1 (de) 1994-06-29 1995-06-28 Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen

Country Status (8)

Country Link
US (2) US6517859B1 (de)
EP (1) EP0767634B1 (de)
JP (1) JPH10506373A (de)
AT (1) ATE261278T1 (de)
DE (1) DE69532673T2 (de)
DK (1) DK0767634T3 (de)
ES (1) ES2217281T3 (de)
WO (1) WO1996000537A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
CA2296056A1 (en) * 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
US7378111B2 (en) * 2002-02-20 2008-05-27 The Trustees Of The University Of Pennsylvania Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease
US20080121141A1 (en) * 2006-11-16 2008-05-29 Haggquist Gregory W Exothermic-enhanced articles and methods for making the same
CA2489139C (en) * 2002-06-12 2012-01-10 Traptek, Llc Encapsulated active particles and methods for making and using the same
SI1610791T1 (sl) 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
WO2005095950A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Method and device for evaluation of pharmaceutical compositions
EP1836161B1 (de) 2004-12-22 2016-07-20 BHI Limited Partnership Verfahren und zusammensetzungen zur behandlung von amyloidassoziierten krankheiten
US20060228420A1 (en) * 2005-03-15 2006-10-12 Queen Mary & Westfield College Pharmaceutical compositions comprising microparticles for delivery into neurons
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
AU2006294644A1 (en) * 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US20070142287A1 (en) * 2005-12-20 2007-06-21 Biomed Solutions, Llc Compositions And Methods For Treatment Of Cancer
CA2841386A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
CN101479331B (zh) * 2006-05-09 2014-04-09 创普太克公司 活性颗粒增强的膜及其制造和使用方法
SI2089417T1 (sl) 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
WO2008122044A2 (en) * 2007-04-02 2008-10-09 Georgia Tech Research Corporation Implantable device for communicating with biological tissue
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
EP2162120B1 (de) * 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
EP2240162A4 (de) * 2007-12-06 2013-10-09 Bend Res Inc Nanoteilchen mit einem nicht-ionisierbaren polymer und einem amin-funktionalisierten methacrylat-copolymer
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
WO2010035261A2 (en) 2008-09-29 2010-04-01 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
BR112012009801A8 (pt) 2009-10-30 2016-08-30 Cns Therapeutics Inc Polipeptídeo neurturina e variante de neurturina
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
CN106519205B (zh) * 2016-10-26 2018-04-10 河南工程学院 一种载药多孔phbv接枝多巴胺微球的制备方法及应用
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
EP3576771B1 (de) 2017-01-31 2022-03-09 Veru Inc. Zusammensetzungen und verfahren zur langzeitfreisetzung von antagonisten des gonadotropinfreisetzenden hormons (gnrh)
WO2018226992A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
CA3073062A1 (en) 2017-08-18 2019-02-21 Adrx, Inc. Tau aggregation peptide inhibitors
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
US12383246B2 (en) 2020-10-12 2025-08-12 Abbott Cardiovascular Systems, Inc. Vessel closure device with improved safety and tract hemostasis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS6048923A (ja) 1983-08-25 1985-03-16 Mitsui Toatsu Chem Inc 微小粒子の製造方法
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4832686A (en) 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US4882686A (en) * 1987-06-22 1989-11-21 Eastman Kodak Company Printing apparatus with improved data formatting circuitry
IL92344A0 (en) 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
ES2058923T3 (es) 1989-06-21 1994-11-01 Univ Brown Res Found Sistema para terapia neurologica.
CH679207A5 (de) 1989-07-28 1992-01-15 Debiopharm Sa
US5225205A (en) 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
JP3187410B2 (ja) 1989-08-10 2001-07-11 住友製薬株式会社 脳内投与用徐放性製剤
ES2185615T3 (es) * 1990-05-16 2003-05-01 Southern Res Inst Uso y liberacion controlada de las microcapsulas para estimular el crecimiento de la fibra nerviosa.

Also Published As

Publication number Publication date
ES2217281T3 (es) 2004-11-01
DE69532673T2 (de) 2005-02-17
US6517859B1 (en) 2003-02-11
EP0767634B1 (de) 2004-03-10
DK0767634T3 (da) 2004-07-19
EP0767634A4 (de) 1998-09-30
US6565875B2 (en) 2003-05-20
US20020094347A1 (en) 2002-07-18
JPH10506373A (ja) 1998-06-23
DE69532673D1 (de) 2004-04-15
EP0767634A1 (de) 1997-04-16
WO1996000537A1 (en) 1996-01-11

Similar Documents

Publication Publication Date Title
DE69532673D1 (de) Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen
ATE226091T1 (de) Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
ATE228832T1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
US5091171B1 (en) Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
CA2182228A1 (en) Codrugs as a method of controlled drug delivery
MX9603489A (es) Peptidos opiodes novedosos para el tratamiento del dolor y uso de los mismos.
AU3402295A (en) Methods and means for drug administration
DE69203596D1 (de) Biologisch abbaubare und biologisch absorbierbare führungskanäle zur verwendung in der behandlung und regenerierung von nerven.
DE69434963D1 (de) Selektiv auf die leber wirkende pharmazeutisch aktive substanz
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
CA2260750A1 (en) Methods for providing safe local anesthesia
MY105073A (en) Transdermal therapeutical system comprising physostigmine as active component and process for the production thereof.
AU2173400A (en) Method for administering agents to the central nervous system
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
ATE361772T1 (de) Behalter zur iontophoretischen verabreichung von medikamenten mit inerten material-bestandteilen
WO2003026489A3 (en) Biopolymer and biopolymer-cell compositions for nerve tissue repair
AU5157596A (en) Biodegradable device
DE69737296D1 (de) Synthetische antisense oligodeoxynukleotide und diese enthaltende pharmazeutische zusammensetzungen
FR2686250B1 (de)
ATE257727T1 (de) Zusammensetzung und system zur iontophoretischen transdermalen abgabe von medikamenten
MXPA01006011A (es) Composicion para tratamiento de quemaduras.
ES2172949T3 (es) Composiciones destinadas para la administracion transcutanea y cutanea de agentes biologicamente activos.
Pużyński et al. Drug-resistance in endogenous depression: I. Refractoriness to antidepressants in patients with depression firstly admitted to a psychiatric clinic.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0767634

Country of ref document: EP

REN Ceased due to non-payment of the annual fee